Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2017
At a glance
- Drugs Tesamorelin (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- 16 Feb 2017 Planned number of patients changed from 115 to 100.
- 16 Feb 2017 Status changed from not yet recruiting to recruiting.
- 24 Oct 2016 Planned End Date changed from 1 Mar 2021 to 1 Nov 2021.